Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2025
Reporting Period: Event-based report for July 22, 2025
Business Overview: The Company is a Delaware corporation focused on developing diagnostic technologies, specifically utilizing flow cytometry for lung health assessment.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
Intellectual Property Milestone: On July 22, 2025, the Company received notification of allowance from the Canadian Patent Office for a patent application.
Patent Details: The patent, titled "System and Method for Determining Lung Health," protects methods for predicting the likelihood of lung cancer using flow cytometry. Specifically, it covers the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum to determine the presence of lung cancer cells.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the patent allowance but does not include forward-looking guidance, financial outlook, or specific management commentary beyond the announcement of the event.
Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in this filing text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional details on the patent scope.
- Confirm the commercialization timeline and regulatory status of the "System and Method for Determining Lung Health" in Canada and other jurisdictions.
- Review recent 10-K or 10-Q filings for the Company's current cash position and runway, as this 8-K contains no financial data.
- Monitor Nasdaq Capital Market trading for BIAF and BIAFW (Warrants) for market reaction to the patent news.